VPS34-IN1
(Synonyms: Vacuolar Protein Sorting 34 Inhibitor 1, Vps34 Inhibitor 1) 目录号 : GC10436A potent and selective inhibitor of Vps34
Cas No.:1383716-33-3
Sample solution is provided at 25 µL, 10mM.
IC50: 25 nM
VPS34-IN1 is a Vps34 inhibitor.
The vacuolar protein sorting 34 (Vps34) class III phosphoinositide 3-kinase (PI3K) phosphorylates phosphatidylinositol (PtdIns) to generate PtdIns(3)P that regulates membrane trafficking processes through its ability to recruit a subset of proteins possessing PtdIns(3)P-binding phox homology (PX) and FYVE domains.
In vitro: VPS34-IN1 was identified to be able to inhibit in-vitro Vps34, but did not significantly inhibit the activity of tested 340 protein kinases or 25 lipid kinases that include all isoforms of class I and class II PI3Ks. Treatment of VPS34-IN1 to cells dose-dependently induced a quick dispersal of a specific PtdIns(3)P-binding probe, without altering the ability of class I PI3K to regulate Akt. Moreover, VPS34-IN1 could also induce a quick ~50-60% loss of SGK3 phosphorylation within 1 min. However, VPS34-IN1 could not inhibit activity of the SGK2 isoform without a PtdIns(3)P-binding PX domain. In addition, the combination of VPS34-IN1 and class I PI3K inhibitor of GDC-0941 resulted in the reduced SGK3 activity ~80-90%. Therefore, these data demonstrated that VPS34-IN1 would be a useful probe to delineate physiological roles of the Vps34 and the combination of class I such as GDC-0941 and class III such as VPS34-IN1 PI3K inhibitors could be used to better analyse the roles and regulation of the elusive class II PI3K [1].
In vivo: So far, there is no animal in vivo data reported.
Clinical trial: Up to now, VPS34-IN1 is still in the preclinical development stage.
Reference:
[1] Bago R et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J.2014 Nov 1;463(3):413-27.
Cas No. | 1383716-33-3 | SDF | |
别名 | Vacuolar Protein Sorting 34 Inhibitor 1, Vps34 Inhibitor 1 | ||
化学名 | 1-((2-((2-chloropyridin-4-yl)amino)-4'-(cyclopropylmethyl)-[4,5'-bipyrimidin]-2'-yl)amino)-2-methylpropan-2-ol | ||
Canonical SMILES | CC(CNC1=NC=C(C(CC2CC2)=N1)C3=NC(NC4=CC(Cl)=NC=C4)=NC=C3)(O)C | ||
分子式 | C21H24ClN7O | 分子量 | 425.91 |
溶解度 | DMSO: 38 mg/mL | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3479 mL | 11.7396 mL | 23.4791 mL |
5 mM | 0.4696 mL | 2.3479 mL | 4.6958 mL |
10 mM | 0.2348 mL | 1.174 mL | 2.3479 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet